시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 반추동물용 백신 시장 규모, 점유율 및 동향 분석 보고서 : 동물 유형별, 백신 유형별, 투여 경로별, 적응증별, 지역별 전망 및 예측(2024-2031년)
Global Ruminant Vaccines Market Size, Share & Trends Analysis Report By Animal Type (Cattle, and Sheep & Goats), By Vaccines Type, By Route of Administration, By Indication, By Regional Outlook and Forecast, 2024 - 2031
상품코드 : 1472432
리서치사 : KBV Research
발행일 : 2024년 04월
페이지 정보 : 영문 283 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,600 ￦ 5,386,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,320 ￦ 6,464,000
PDF (Multi User License) help
PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,048 ￦ 9,049,000
PDF (Corporate User License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

반추동물용 백신 시장 규모는 예측 기간 동안 6.7%의 연평균 복합 성장률(CAGR)로 성장하여 2031년까지 57억 달러에 달할 것으로 예상됩니다.

그러나 백신 접종 프로그램은 특히 제한된 자원으로 소규모 또는 중규모로 운영되는 농가의 경우 많은 자금 투자가 필요합니다. 백신 구매 비용과 보관, 관리, 수의사 서비스 등 관련 비용은 농장의 예산을 압박할 수 있습니다. 또한 백신의 생산, 유통 및 보관에는 물류상의 문제가 수반되며, 이는 높은 비용으로 이어질 수 있습니다. 따라서 백신의 높은 비용은 시장 성장을 저해하고 있습니다.

코로나19 팬데믹은 전 세계 공급망을 혼란에 빠뜨렸고, 백신을 포함한 동물용 백신의 생산과 유통에 영향을 미쳤습니다. 이동 제한, 봉쇄 조치 및 운송 중단으로 인해 백신 생산 지연, 원자재 부족 및 백신 배포에 대한 물류 문제가 발생했습니다. 마찬가지로, 팬데믹 기간 동안 의료 자원과 관심은 주로 코로나19와의 싸움에 집중되었습니다. 이러한 변화는 반추 동물 개체군의 질병 전파 역학 및 백신 접종 전략에 영향을 미쳐 백신 수요에 영향을 미쳤습니다. 따라서 코로나19 팬데믹은 시장에 부정적인 영향을 미쳤습니다.

목차

제1장 시장 범위와 조사 방법

제2장 시장 요람

제3장 시장 개요

제4장 반추동물용 백신 시장에서 전개되고 있는 최근 전략

제5장 세계 시장 : 동물 유형별

제6장 세계 시장 : 백신 유형별

제7장 세계 시장 : 투여 경로별

제8장 세계 시장 : 적응증별

제9장 세계 시장 : 지역별

제10장 기업 개요

제11장 반추동물용 백신 시장을 위한 성공 필수 조건

LSH
영문 목차

영문목차

The Global Ruminant Vaccines Market size is expected to reach $5.7 billion by 2031, rising at a market growth of 6.7% CAGR during the forecast period.

BVD is a highly economically significant disease in cattle, causing substantial losses to the livestock industry worldwide. Effective vaccinations to prevent and control BVD are in high demand due to the economic burden of outbreaks. Consequently, the BVD infection segment would acquire nearly, 30% market share by2031. The disease reduces productivity, including decreased milk production, weight loss, reduced reproductive performance, increased veterinary costs, and increased susceptibility to secondary infections.

The demand for foods high in protein, such as meat, milk, and dairy products, is rising along with the world's population. Additionally, urbanization trends often lead to changes in dietary habits. This creates a substantial market opportunity for ruminant vaccines, as producers strive to comply with regulations and ensure the health and safety of their animals. Thus, the increasing demand for livestock products drives the market's growth. Additionally, the emergence and spread of infectious illnesses are made possible by the intensification of livestock production systems, which is a result of population growth and an increase in the demand for animal products. Therefore, the growing prevalence of infectious diseases is propelling the growth of the market.

However, Vaccination programs require significant financial investment from farmers, particularly those operating on small or medium scales with limited resources. The cost of purchasing vaccines and associated expenses such as storage, administration, and veterinary services can strain farm budgets. Also, vaccines' production, distribution, and storage entail logistical challenges that can contribute to their high cost. Therefore, the high cost of vaccines Is impeding the market's growth.

The COVID-19 pandemic disrupted global supply chains, affecting the production and distribution of veterinary vaccines, including vaccines. Restrictions on movement, lockdown measures, and transportation disruptions led to delays in vaccine manufacturing, shortages of raw materials, and logistical challenges in vaccine distribution. Similarly, healthcare resources and attention primarily focused on combating COVID-19 during the pandemic. These changes had implications for disease transmission dynamics and vaccination strategies in ruminant populations, influencing vaccine demand. Thus, the COVID-19 pandemic had a negative impact on the market.

By Animal Type Analysis

Based on animal type, the market is divided into cattle and sheep & goats. The sheep & goats segment procured a 14.95% revenue share in the market in 2023. The sheep and goat industry are experiencing growth globally, driven by increasing demand for meat, milk, and fiber products. There is an increasing focus on high-quality, sustainable animal production as the population expands and customer demands change. This production growth creates a greater need for disease prevention and control measures, including vaccination, to ensure the health and productivity of sheep and goat populations.

By Vaccines Type Analysis

On the basis of vaccines type, the market is segmented into modified/ attenuated live, inactivated (killed), and others. In 2023, the inactivated (killed) segment attained a 34.15% revenue share in the market. Inactivated vaccines are generally more stable and have longer shelf lives. Inactivated vaccines' stability and shelf life make them suitable for use in remote or resource-limited areas.

By Route of Administration Analysis

By route of administration, the market is bifurcated into injectable and intranasal. The intranasal segment procured a 5.68% revenue share in the market in 2023. Intranasal vaccines offer a non-invasive route of administration, as they are administered through the nasal passages rather than by injection. This non-invasive approach reduces animal stress and discomfort during vaccination, making intranasal vaccines particularly suitable for use in ruminants that may be difficult to handle or restrain for injection.

By Indication Analysis

Based on indication, the market is categorized into BVD infection, bovine respiratory diseases (BRD), leptospirosis, clostridial diseases, diarrhea/ scours, FMD, and others. The clostridial diseases segment attained a 16.76% revenue share in the market in 2023. Clostridial diseases, such as blacklegs (Clostridium chauvoei), malignant edema (C. septicum), tetanus (C. tetani), and enterotoxemia (C. perfringens types C and D), can cause severe and often fatal infections in livestock. The devastating impact of clostridial diseases on animal health drives demand for effective vaccines to prevent disease outbreaks and reduce mortality rates.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 36% revenue share in the ruminant vaccines market in 2023. North American livestock producers prioritize animal health and welfare to maintain the quality and integrity of their products. By investing in vaccination programs and disease management strategies, North American producers aim to ensure the well-being of their livestock and meet consumer expectations for safe and wholesome meat and dairy products.

Recent Strategies Deployed in the Market

Mar-2024: Boehringer Ingelheim International GmbH came into partnership with Square Pharmaceuticals, which manufactures and markets pharmaceuticals and animal health products, to launch Aftovaxpur, an advanced FMD vaccine for ruminants in Bangladesh. Through this partnership, the company will enhance the safety and reliability of vaccines to combat this outbreak.

Aug-2023: Zoetis, Inc. launched Vetscan Mastigram+, a rapid on-farm mastitis diagnostic, in several markets across Europe. This product launch will help to prudent use of antimicrobials and expand the company's portfolio.

Jun-2023: Zoetis, Inc. launched Protivity, the first in-class modified live vaccine approved to protect healthy beef and dairy calves against respiratory disease caused by M. bovis infection in the EU. This will protect healthy beef and dairy calves against respiratory disease caused by Mycoplasma bovis (M. bovis).

Dec-2022: Ceva Sante Animale acquired Zoovet, a company specializing in the production and marketing of animal health products, and Biotecnofe, a biotech start-up developing innovative products to be distributed by Zoovet, to increase our footprint in Latin America. Through this acquisition, the company will provide solutions that help farmers keep their animals healthy.

Sep-2022: Boehringer Ingelheim International GmbH added Fencovis, the first calf scour vaccine with a prevention claims against E. coli F5 and bovine rotavirus, to its vaccine portfolio. Through this launch, the company will provide passive immunity to calves through the cows' maternal colostrum.

List of Key Companies Profiled

Global Ruminant Vaccines Market Report Segmentation

By Animal Type

By Vaccines Type

By Route of Administration

By Indication

By Geography

Table of Contents

Chapter 1.Market Scope & Methodology

Chapter 2.Market at a Glance

Chapter 3.Market Overview

Chapter 4.Recent strategies deployed in Ruminant Vaccines Market

Chapter 5.Global Ruminant Vaccines Market by Animal Type

Chapter 6.Global Ruminant Vaccines Market by Vaccines Type

Chapter 7.Global Ruminant Vaccines Market by Route of Administration

Chapter 8.Global Ruminant Vaccines Market by Indication

Chapter 9.Global Ruminant Vaccines Market by Region

Chapter 10.Company Profiles

Chapter 11.Winning strategies of Ruminant Vaccines Market

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기